Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial
Author:
Publisher
Elsevier BV
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference24 articles.
1. Global hepatitis report, 2017;World Health Organization,2017
2. Global epidemiology and burden of HCV infection and HCV-related disease;Thrift;Nat Rev Gastroenterol Hepatol,2016
3. Benefits of direct-acting antivirals for hepatitis C;Lok;Ann Intern Med,2017
4. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort;Welzel;Gut,2016
5. Safety and efficacy of daclatasvir–sofosbuvir in HCV genotype 1–mono-infected patients;Pol;J Hepatol,2017
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01
2. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4;Current Drug Safety;2023-05
3. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients;Egyptian Liver Journal;2022-09-09
4. A fuzzy logic-based computational method for the repurposing of drugs against COVID-19;BioImpacts;2021-08-10
5. A clinical case of ulcerative colitis in a patient with viral hepatitis;South Russian Journal of Therapeutic Practice;2020-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3